Indian government is working actively to stop black marketing of medicines in the future

  • News
  • June 16, 2017

New Delhi : National Pharmaceutical Pricing Authority (NPPA) has taken one step forward and fixed ceiling price (CP) of 1 scheduled formulation and Maximum Retail Price (MRP) of 4 formulations to stop black marketing.

NPPA revised prices under Drugs (Price Control) Amendment Order, 2016 (under DPCO, 2013) and retail prices of 4 formulations under DPCO, 2013. Clotrimazol’s ceiling price is fixed now and NPPA officials also added that the manufacturers of scheduled formulations, selling the branded / generic / both versions of scheduled formulations at a price higher than the ceiling price [plus local taxes as applicable] fixed and notified by the government, shall revise the prices.

Retail Price of four medicines Pacimol 10mg/ml Infusion, Pacimol MF tablet, Ten- DC M 500 tablet and Ten – DC M 1000 tablet MRP has been fixed under DPCO, 2013. Officials said we are now covering common medicines and started with major drugs and products like stents. The allowed price change is in the range of 10% to 15% only.  We are ensuring this step will definitely curb black marketing and benefits consumers.

To help consumers to aware them about the price change, retailers expected to show main and supplementary list if any, as furnished by the manufacturer. Deposits should be made with an interest in the case of overcharging under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

NPPA notified all manufacturers to maintain MRP in case if it is lower than capped price. Pharma manufacturers permitted to add local taxes if they have paid them or if it is payable to the government on the ceiling price mentioned.

  • Related Posts

    Govt Temporarily Eases BIS Rules for Medical Device Parts

    New Delhi, August 6, 2025 — In a relief to the medical-devices industry, the Centre has temporarily eased BIS compliance for certain steel inputs used to make surgical blades, scalpels,…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    Piyush Goyal meets pharma industry leaders to discuss R&D, competitiveness boost

    Senores Pharma to Buy Two Teva ANDAs

    Senores Pharma to Buy Two Teva ANDAs

    Lab-grown rabies antibodies show promise as cheaper, safer alternative

    Lab-grown rabies antibodies show promise as cheaper, safer alternative

    Lilly launches Mounjaro KwikPen in India

    Lilly launches Mounjaro KwikPen in India